IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Saturday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

Shares of IRIX opened at $1.77 on Friday. The stock has a 50 day moving average of $1.68 and a 200 day moving average of $1.83. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $29.45 million, a price-to-earnings ratio of -2.64 and a beta of 0.82. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The business had revenue of $11.58 million for the quarter. During the same quarter in the prior year, the firm earned ($0.11) EPS.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.